Review





Similar Products

96
MedChemExpress wnt signaling pathway inhibitor xav939
Wnt Signaling Pathway Inhibitor Xav939, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pmc13011191-109-1-6?v=MedChemExpress
Average 96 stars, based on 1 article reviews
wnt signaling pathway inhibitor xav939 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc cell signaling pathways
Cell Signaling Pathways, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pmc12907801-174-0-0?v=Cell+Signaling+Technology+Inc
Average 86 stars, based on 1 article reviews
cell signaling pathways - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Exosome Diagnostics 953 exosome mediated pi3k akt mtor signaling pathway
953 Exosome Mediated Pi3k Akt Mtor Signaling Pathway, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pm42320774-458-1-2?v=Exosome+Diagnostics
Average 86 stars, based on 1 article reviews
953 exosome mediated pi3k akt mtor signaling pathway - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Galectin Therapeutics tgf β smad signaling pathway
Galectin-1 promotes MMT in HPMCs <t>through</t> <t>the</t> <t>TGF-β/Smad</t> signaling pathway (A–D) WB analysis of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels ( n = 3). (E–H) WB confirmed E-cadherin and vimentin expression in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1. Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.
Tgf β Smad Signaling Pathway, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pmc13206751-86-5-0?v=Galectin+Therapeutics
Average 86 stars, based on 1 article reviews
tgf β smad signaling pathway - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Takeda g protein coupled receptor 5 tgr5 associated signaling pathways
Galectin-1 promotes MMT in HPMCs <t>through</t> <t>the</t> <t>TGF-β/Smad</t> signaling pathway (A–D) WB analysis of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels ( n = 3). (E–H) WB confirmed E-cadherin and vimentin expression in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1. Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.
G Protein Coupled Receptor 5 Tgr5 Associated Signaling Pathways, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pm42296782-239-14-13?v=Takeda
Average 86 stars, based on 1 article reviews
g protein coupled receptor 5 tgr5 associated signaling pathways - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Dezhou Deyao Pharmaceutical Co Ltd signaling pathways
Galectin-1 promotes MMT in HPMCs <t>through</t> <t>the</t> <t>TGF-β/Smad</t> signaling pathway (A–D) WB analysis of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels ( n = 3). (E–H) WB confirmed E-cadherin and vimentin expression in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1. Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.
Signaling Pathways, supplied by Dezhou Deyao Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pm42278056-192-7-17?v=Dezhou+Deyao+Pharmaceutical+Co+Ltd
Average 86 stars, based on 1 article reviews
signaling pathways - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Medicago nod factor signal transduction 2 pathway
Galectin-1 promotes MMT in HPMCs <t>through</t> <t>the</t> <t>TGF-β/Smad</t> signaling pathway (A–D) WB analysis of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels ( n = 3). (E–H) WB confirmed E-cadherin and vimentin expression in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1. Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.
Nod Factor Signal Transduction 2 Pathway, supplied by Medicago, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pm42267652-588-3-10?v=Medicago
Average 86 stars, based on 1 article reviews
nod factor signal transduction 2 pathway - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Medicago nodulation signaling pathway 2
Galectin-1 promotes MMT in HPMCs <t>through</t> <t>the</t> <t>TGF-β/Smad</t> signaling pathway (A–D) WB analysis of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels ( n = 3). (E–H) WB confirmed E-cadherin and vimentin expression in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1. Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.
Nodulation Signaling Pathway 2, supplied by Medicago, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pm42251962-517-5-11?v=Medicago
Average 86 stars, based on 1 article reviews
nodulation signaling pathway 2 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Musashi Engineering Inc rapamycin signaling pathway
Clinical images of patient 1 at baseline (A) , 8 wks on <t>sirolimus</t> twice daily (B) , and 16 wks on sirolimus twice daily (C) .
Rapamycin Signaling Pathway, supplied by Musashi Engineering Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pmc13145876-9-14-10?v=Musashi+Engineering+Inc
Average 86 stars, based on 1 article reviews
rapamycin signaling pathway - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

97
MedChemExpress wnt signaling pathway activator laduviglusib
Clinical images of patient 1 at baseline (A) , 8 wks on <t>sirolimus</t> twice daily (B) , and 16 wks on sirolimus twice daily (C) .
Wnt Signaling Pathway Activator Laduviglusib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signaling+pathway/pmc13011191-109-10-15?v=MedChemExpress
Average 97 stars, based on 1 article reviews
wnt signaling pathway activator laduviglusib - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier

Image Search Results


Galectin-1 promotes MMT in HPMCs through the TGF-β/Smad signaling pathway (A–D) WB analysis of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels ( n = 3). (E–H) WB confirmed E-cadherin and vimentin expression in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1. Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.

Journal: iScience

Article Title: Gastric cancer-secreted galectin-1 promotes peritoneal mesothelial-mesenchymal transition to prime peritoneal metastasis soil

doi: 10.1016/j.isci.2026.115908

Figure Lengend Snippet: Galectin-1 promotes MMT in HPMCs through the TGF-β/Smad signaling pathway (A–D) WB analysis of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels ( n = 3). (E–H) WB confirmed E-cadherin and vimentin expression in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1. Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.

Article Snippet: Galectin-1-induced peritoneal MMT through the TGF-β/Smad signaling pathway is an important mechanism for GCPM, offering a potential target for GC treatment.

Techniques: Expressing

Activation of the TGF-β/Smad signaling pathway promotes MMT in HPMCs (A–D) Representative immunofluorescence images of E-cadherin and vimentin in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1 (Scale bars, 50 μm) ( n = 3). (E–H) Representative immunofluorescence images of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression or CM-OE- LGALS1 supplemented with ITD1 (Scale bars, 50 μm) ( n = 3). Data are represented as mean ± SD.∗ p < 0.05, ∗∗ p < 0.01, NS, p > 0.05.

Journal: iScience

Article Title: Gastric cancer-secreted galectin-1 promotes peritoneal mesothelial-mesenchymal transition to prime peritoneal metastasis soil

doi: 10.1016/j.isci.2026.115908

Figure Lengend Snippet: Activation of the TGF-β/Smad signaling pathway promotes MMT in HPMCs (A–D) Representative immunofluorescence images of E-cadherin and vimentin in HMrSV5 cells treated with CM from SGC-7901 cells (A and B) and HGC-27 cells (C and D) with different LGALS1 expression levels or CM-OE- LGALS1 supplemented with ITD1 (Scale bars, 50 μm) ( n = 3). (E–H) Representative immunofluorescence images of TGF-β1 and p -Smad2/3 in HMrSV5 cells treated with CM from SGC-7901 cells (E and F) and HGC-27 cells (G and H) with different LGALS1 expression or CM-OE- LGALS1 supplemented with ITD1 (Scale bars, 50 μm) ( n = 3). Data are represented as mean ± SD.∗ p < 0.05, ∗∗ p < 0.01, NS, p > 0.05.

Article Snippet: Galectin-1-induced peritoneal MMT through the TGF-β/Smad signaling pathway is an important mechanism for GCPM, offering a potential target for GC treatment.

Techniques: Activation Assay, Immunofluorescence, Expressing

TGF-β/Smad signaling pathway is activated in peritoneal tissues undergoing MMT, and galectin-1 enhances GC cell adhesion to HPMCs via this pathway (A–C) Representative images of immunofluorescence for TGF-β1 (A) and p -Smad2/3 (B) in peritoneal tissues without or with MMT (×400 magnification). (C) Comparison of the relative fluorescence density of TGF-β1 and p -Smad2/3 in peritoneal tissues without or with MMT ( n = 6). (D and E) GC cells incubated with Calcein-AM were added to HMrSV5 cells treated with CM from SGC-7901 cells (D) or HGC-27 cells (E) or with different LGALS1 expression levels (Scale bars, 100 μm) ( n = 3). (F and G) Mean IODs of SGC-7901 cells (F) and HGC-27 cells (G) adherent to HMrSV5 cells ( n = 3). Data are represented as mean ± SD.∗∗ p < 0.01, NS, p > 0.05.

Journal: iScience

Article Title: Gastric cancer-secreted galectin-1 promotes peritoneal mesothelial-mesenchymal transition to prime peritoneal metastasis soil

doi: 10.1016/j.isci.2026.115908

Figure Lengend Snippet: TGF-β/Smad signaling pathway is activated in peritoneal tissues undergoing MMT, and galectin-1 enhances GC cell adhesion to HPMCs via this pathway (A–C) Representative images of immunofluorescence for TGF-β1 (A) and p -Smad2/3 (B) in peritoneal tissues without or with MMT (×400 magnification). (C) Comparison of the relative fluorescence density of TGF-β1 and p -Smad2/3 in peritoneal tissues without or with MMT ( n = 6). (D and E) GC cells incubated with Calcein-AM were added to HMrSV5 cells treated with CM from SGC-7901 cells (D) or HGC-27 cells (E) or with different LGALS1 expression levels (Scale bars, 100 μm) ( n = 3). (F and G) Mean IODs of SGC-7901 cells (F) and HGC-27 cells (G) adherent to HMrSV5 cells ( n = 3). Data are represented as mean ± SD.∗∗ p < 0.01, NS, p > 0.05.

Article Snippet: Galectin-1-induced peritoneal MMT through the TGF-β/Smad signaling pathway is an important mechanism for GCPM, offering a potential target for GC treatment.

Techniques: Immunofluorescence, Comparison, Fluorescence, Incubation, Expressing

Galectin-1 promotes GCPM through the TGF-β/Smad signaling pathway (A) Representative images of the GCPM animal model established in this study. (B) H&E staining confirmed that the peritoneal nodules were metastatic carcinomas (×400 magnification). (C–E) Representative immunofluorescence images of E-cadherin and vimentin (C), TGF-β1 (D) and p -Smad2/3 (E) in the peritoneum of model animals (×400 magnification). (F) The PCI of mice in different groups ( n = 6). (G and H) The mean fluorescence density of vimentin and E-cadherin ( n = 6). (I and J) The relative fluorescence density of TGF-β1 and p -Smad2/3 ( n = 6). Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.

Journal: iScience

Article Title: Gastric cancer-secreted galectin-1 promotes peritoneal mesothelial-mesenchymal transition to prime peritoneal metastasis soil

doi: 10.1016/j.isci.2026.115908

Figure Lengend Snippet: Galectin-1 promotes GCPM through the TGF-β/Smad signaling pathway (A) Representative images of the GCPM animal model established in this study. (B) H&E staining confirmed that the peritoneal nodules were metastatic carcinomas (×400 magnification). (C–E) Representative immunofluorescence images of E-cadherin and vimentin (C), TGF-β1 (D) and p -Smad2/3 (E) in the peritoneum of model animals (×400 magnification). (F) The PCI of mice in different groups ( n = 6). (G and H) The mean fluorescence density of vimentin and E-cadherin ( n = 6). (I and J) The relative fluorescence density of TGF-β1 and p -Smad2/3 ( n = 6). Data are represented as mean ± SD. ∗∗ p < 0.01, NS, p > 0.05.

Article Snippet: Galectin-1-induced peritoneal MMT through the TGF-β/Smad signaling pathway is an important mechanism for GCPM, offering a potential target for GC treatment.

Techniques: Animal Model, Staining, Immunofluorescence, Fluorescence

Clinical images of patient 1 at baseline (A) , 8 wks on sirolimus twice daily (B) , and 16 wks on sirolimus twice daily (C) .

Journal: JAAD Case Reports

Article Title: Treatment of extramammary Paget’s disease with sirolimus: A case series

doi: 10.1016/j.jdcr.2025.10.021

Figure Lengend Snippet: Clinical images of patient 1 at baseline (A) , 8 wks on sirolimus twice daily (B) , and 16 wks on sirolimus twice daily (C) .

Article Snippet: While the pathogenesis of EMPD is not completely understood, the Musashi-1- mammalian target of rapamycin signaling pathway is thought to play a role in disease development.

Techniques:

Clinical images of patient 3 at baseline (A) , 4 wks on sirolimus twice daily (B) , and 8 wks on sirolimus twice daily (C) .

Journal: JAAD Case Reports

Article Title: Treatment of extramammary Paget’s disease with sirolimus: A case series

doi: 10.1016/j.jdcr.2025.10.021

Figure Lengend Snippet: Clinical images of patient 3 at baseline (A) , 4 wks on sirolimus twice daily (B) , and 8 wks on sirolimus twice daily (C) .

Article Snippet: While the pathogenesis of EMPD is not completely understood, the Musashi-1- mammalian target of rapamycin signaling pathway is thought to play a role in disease development.

Techniques: